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Background: Fibroblast growth factor 21 (FGF21), a glucose and lipid metabolic regulator, has recently been
demonstrated to be associated with cardiovascular diseases (CVD) such as carotid atherosclerosis, coronary heart
disease and carotid artery plaques. However, the relationship between circulating FGF21 and subclinical atherosclerosis
or atherosclerosis of other arteries such as the femoral and iliac artery remains unclear. In this study, we evaluated the
association of serum FGF21 with intima-media thickness (IMT) and subclinical atherosclerosis in type 2 diabetic patients.
Methods: Serum FGF21 levels were detected by enzyme-linked immunosorbent assay in 212 newly diagnosed
type 2 diabetic patients without clinical symptoms of atherosclerosis or cardiovascular diseases. IMT of the carotid,
femoral, and iliac arteries were measured by high-resolution B-mode ultrasound to determine the presence of
subclinical atherosclerosis, which was defined as having an IMT > 1.0 mm and/or plaque on one or more of the
three arteries without any clinical manifestations. The relationship between serum FGF21 levels and subclinical
atherosclerosis was analyzed.
Results: Serum FGF21 levels were significantly higher in patients with subclinical atherosclerosis compared to
those without [261.3 (135.1–396.4) versus 144.9 (95.9–223.0) ng/L, P < 0.001]. These differences were also observed
in both men and women with subclinical atherosclerosis compared to their respective groups without [men: 243.2
(107.6–337.0) versus 136.8 (83.6–212.8) ng/L, P = 0.048; women: 292.4 (174.2–419.9) versus 160.4 (115.3–258.5) ng/L,
P = 0.001]. Moreover, serum FGF21 levels showed a significantly positive correlation with carotid IMT in women (r = 0.23,
P = 0.018) and with iliac IMT in both genders (women: r = 0.27, P = 0.005; men: r = 0.22, P = 0.024). Multiple logistic
regression analysis further showed that serum FGF21 was an independent impact factor for subclinical atherosclerosis
in patients with type 2 diabetes.
Conclusions: Serum FGF21 is elevated in newly diagnosed type 2 diabetes, and positively correlates with carotid
and iliac lesions in patients with subclinical atherosclerosis, especially in women. High levels of FGF21 may be a
compensatory reaction to offset atherosclerosis.
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Fibroblast growth factor 21 (FGF21) is a member of the
endocrine FGF subfamily, which also includes FGF19
and FGF23 [1]. Unlike classical FGF molecules that act
in an autocrine manner, these three members are present
in the circulation and possess hormone-like activities [2].
A growing body of evidence demonstrates that FGF21 is
an important metabolic regulator with multiple beneficial
effects on glucose and lipid homeostasis in animals [3, 4].
Systemic administration of recombinant FGF21 reduced
plasma glucose and lipids to near normal levels in both
ob/ob and db/db mouse models as well as diabetic mon-
keys [3, 4]. Likewise, FGF21 transgenic mice rendered
protection against diet-induced obesity and metabolic
disorders [4].
Despite the multiple salutatory effects of FGF21 on
glucose and lipid metabolism in animals, circulating
FGF21 levels are elevated in obese subjects [5, 6] and
patients with impaired glucose tolerance [7], type 2 dia-
betes mellitus [5, 7, 8], dyslipidemia [9], and nonalco-
holic fatty liver disease (NAFLD) [10, 11]. Additionally,
circulating FGF21 levels are positively associated with
body adiposity index, insulin resistance [6], hepatic lipid
levels [11], and markers of liver injury [9]. Thus, it has
been proposed that the elevated level of FGF21 (a condi-
tion termed “hyper-FGF21-nemia”) in obese subjects is
due to a decrease in the number of responsive FGF21 re-
ceptors on target cells, a phenomenon known as FGF21
resistance [12].
Recently, several reports have examined the role of
FGF21 in cardiovascular diseases (CVD) in humans. Ele-
vated serum FGF21 levels have been shown in subjects
with coronary heart disease (CHD) [13, 14] and was as-
sociated with both carotid atherosclerosis in women and
carotid artery plaques in type 2 diabetes subjects [15,
16]. However, circulating FGF21 levels in type 2 diabetic
patients with or without subclinical atherosclerosis or its
association with atherosclerosis of other arteries such as
the femoral and iliac artery remain unclear. In this study,
we assessed the relationship between circulating FGF21
and carotid, femoral and iliac intima-media thickness
(IMT) as well as subclinical atherosclerosis in patients
with newly diagnosed type 2 diabetes.
Methods
Participants
Our study consisted of 212 patients who were diagnosed
within 1 year with type 2 diabetes and recruited from
the Diabetes Center, the Second Xiangya Hospital, Cen-
tral South University. All patients were enrolled in the
Chinese National Tenth and Eleventh Five Tackling Key
Project from 2002 to 2007. Type 2 diabetes was diag-
nosed according to the American Diabetes Association
criteria [17]. Exclusion criteria were clinical symptomsof atherosclerosis; presence of CVD (a history of
physician-diagnosed myocardial infarction, angina, heart
failure, stroke, or transient ischemic attack or who had
undergone an invasive cardiovascular procedure); dia-
betic nephropathy or diabetic retinopathy; or severe liver
and kidney dysfunction.
Hypertension was defined as having a blood pressure
of ≥140/90 mm Hg, or if the patient was regularly taking
antihypertensive medications. Dyslipidemia was diag-
nosed as having one or more of the following criteria:
(1) fasting triglyceride (TG) ≥ 1.7 mmol/L; (2) high-
density lipoprotein-cholesterol (HDL-c) < 1.30 mmol/L
in female and < 1.0 mmol/L in male; (3) low-density
lipoprotein-cholesterol (LDL-c) ≥ 3.4 mmol/L; (4) already
on lipid-lowering drug according to the United States
Adult Treatment Panel III [18]. Central obesity was
defined as a waist circumference (WC) >90 cm for
men, >80 cm for women. Smoking referred to both
current and past smokers, whereas nonsmoker referred to
those who never smoked.
This study was performed with the approval of the In-
stitutional Review Board of the Second Xiangya Hospital,
Central South University, and written informed consent
was obtained from each patient.
Physical and biochemical assessment
All patients were assessed after an overnight fasting.
Anthropometric measurements including height, body
weight, body mass index (BMI), WC and blood pressure
were taken. BMI was calculated as weight divided by
squared-height (kg/m2). Blood pressure was measured
on the right arm with the patient seated for at least
10 min. WC was measured midway between the lower
rib margin and iliac crest. Detailed family histories, in-
cluding history of CVD, were obtained and evaluated
from a questionnaire. Blood was drawn for fasting
glucose, insulin, cholesterol, TG and hemoglobin A1C
(HbA1c) levels. Plasma glucose, serum cholesterol, and
TG levels were measured enzymatically. Serum insulin
was detected using chemiluminescent immunoassays.
HbA1c was determined by an ion exchange HPLC
method. A human FGF21 enzyme-linked immunosorbent
assay (ELISA) kit established in our laboratory (Antibody
and Immunoassay Services, the University of Hong Kong)
was used to determine serum FGF21 levels [8]. The intra-
and inter-assay coefficients of variance were 4.0–5.0 %
and 3.5–10.2 %, respectively.
Vascular ultrasound measurement
The IMT of common carotid, femoral and common iliac
arteries on the right side were evaluated by high-resolution
B-mode ultrasound (128XP/10 system; Acuson, Mountain
View, California, USA). The measurements of IMT were
made at the site of greatest thickness. Plaque was defined
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lumen with a thickness of at least 50 % more than the adja-
cent intima-media complex. The definition of subclinical
atherosclerosis was having an IMT > 1.0 mm and/or
plaque on one or more of the three arteries without any
clinical manifestations [19, 20].
Statistical analysis
All statistical analyses were performed with Statistical
Package for Social Science Version 16.0 (SPSS 16.0, Inc.,
Chicago, IL). Data were expressed as a mean ± SD or
median with interquartile range, as appropriate. Data
that were not normally distributed, as determined using
the Kolmogorov-Smirnov test, were logarithmically trans-
formed before analysis. Correlations between FGF21 and
biochemical variables were analyzed with Pearson correl-
ation. Comparisons between groups were performed using
χ2 tests for categorical variables and independent-samples
T test for continuous variables as indicated. Multiple lo-
gistic regression analysis was done to determine independ-
ent factors of subclinical atherosclerosis, and included
variables which were biologically likely to be related with
atherosclerotic status. Two-sided P values <0.05 were
considered statistically significant.Table 1 Clinical and biochemical characteristics of the study patient
Parameters All patients (n = 212)
Age, year 54.1 ± 8.5
Family history of cardiovascular diseases, % 45.8
Current/past smoker, % 38.2
Body mass index, kg/m2 24.5 ± 2.8
Waist circumference, cm 87.2 ± 8.2
Central obesity, % 52.8
Fasting glucose, mmol/L 7.8 ± 3.3
HbA1c, % 7.7 ± 2.4
Fasting insulina, mIU/L 13.3 (9.0–19.0)
Systolic blood pressure, mm Hg 119.1 ± 17.2
Diastolic blood pressure, mm Hg 76.6 ± 10.7
Hypertension, % 23.1
Triglyceridesa, mmol/L 1.62 (1.16–2.53)
Low-density lipoprotein-cholesterol, mmol/L 3.1 ± 1.0
High-density lipoprotein-cholesterol, mmol/L 1.3 ± 0.4
Dyslipidemia, % 73.1
Carotid intima-media thickness, mm 0.75 ± 0.20
Femoral intima-media thickness, mm 0.77 ± 0.23
Iliac intima-media thickness, mm 0.85 ± 0.22
Subclinical atherosclerosis, % 20.8
Fibroblast growth factor 21a, ng/L 154.0 (105.6–283.3)
Data presented as mean ± SD or median (interquartile range)
aLog-transformed before analysisResults
The physical and biochemical characteristics of all type
2 diabetic patients including FGF21 levels, IMT, and car-
diovascular risks are summarized in Table 1. Compared
with women, men had similar percentage of subclinical
atherosclerosis and FGF21. For the established cardio-
vascular risk factors, men had higher WC, serum TG,
and percentage of current or past smokers, but a lower
HDL-c level compared to women (for WC and TG,
P = 0.001; for smokers and HDL-c, P < 0.001). In addition,
women were older and had higher systolic blood pressure
(P = 0.011 and P = 0.046, respectively).
In men, serum FGF21 levels positively correlated
with fasting glucose and TG (P = 0.034 and P = 0.042,
respectively, Table 2). In women, serum FGF21 levels
correlated positively with WC, fasting glucose and TG
(P = 0.033, P = 0.035 and P = 0.024, respectively). FGF21
levels also showed a significantly positive correlation
with carotid IMT in women (r = 0.23, P = 0.018, Fig. 1a)
as well as iliac IMT in both genders (women: r = 0.27,
P = 0.005, Table 1, Fig. 1b; men: r = 0.22, P = 0.024,
Fig. 1c). Furthermore, serum FGF21 levels were strikingly
higher in patients with subclinical atherosclerosis com-
pared to patients without subclinical atherosclerosiss
Men (n = 107) Women (n = 105) P Value (Men vs Women)
52.6 ± 9.7 55.6 ± 6.9 0.011
43.9 47.6 0.589
70.1 5.7 <0.001
24.9 ± 2.7 24.2 ± 2.8 0.069
89.1 ± 8.2 85.2 ± 7.8 0.001
34.6 71.4 <0.001
7.6 ± 2.5 8.1 ± 3.9 0.236
7.8 ± 2.3 7.7 ± 2.5 0.736
14.0 (9.3–18.0) 12.1 (9.0–21.0) 0.806
116.7 ± 15.6 121.5 ± 18.5 0.046
77.1 ± 10.4 76.1 ± 11.0 0.488
19.6 26.7 0.224
1.87 (1.24–3.31) 1.51 (1.11–2.07) 0.001
3.0 ± 1.1 3.1 ± 0.9 0.501
1.2 ± 0.4 1.4 ± 0.3 <0.001
72.9 73.3 0.943
0.75 ± 0.19 0.75 ± 0.21 0.955
0.75 ± 0.18 0.79 ± 0.27 0.217
0.85 ± 0.23 0.85 ± 0.21 0.953
19.6 21.9 0.683
142.4 (86.1–269.8) 175.9 (125.1–309.0) 0.137
Table 2 Correlations of Serum FGF21 levels with various clinical and biochemical parameters
Men (n = 107) Women (n = 105)
r P value r P value
Age, year 0.10 0.302 0.15 0.129
Body mass index, kg/m2 −0.01 0.930 −0.02 0.848
Waist circumference, cm 0.03 0.780 0.21 0.033
Systolic blood pressure, mmHg 0.07 0.457 0.04 0.694
Diastolic blood pressure, mmHg 0.03 0.776 −0.04 0.699
Fasting glucose, mmol/L 0.21 0.034 0.21 0.035
HbA1c, % −0.11 0.258 0.03 0.738
Fasting insulina, mIU/L −0.11 0.254 0.04 0.691
High-density lipoprotein-cholesterol, mmol/L 0.10 0.324 −0.01 0.919
Low-density lipoprotein-cholesterol, mmol/L 0.14 0.165 0.04 0.716
Triglyceridesa 0.20 0.042 0.22 0.024
Carotid intima-media thickness, mm 0.00 0.997 0.23 0.018
Femoral intima-media thickness, mm 0.02 0.872 0.15 0.132
Iliac intima-media thickness, mm 0.22 0.024 0.27 0.005
aLog-transformed before analyses
Fig. 1 Correlations between FGF21 levels and IMT. Correlations between serum FGF21 levels and carotid IMT (a, n = 105) or iliac IMT (b, n = 105)
in women with type 2 diabetes; correlation between serum FGF21 levels and iliac IMT (c, n = 107) in men with type 2 diabetes
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P < 0.001]. These differences were observed for both gen-
ders with subclinical atherosclerosis compared to their re-
spective groups without [men: 243.2 (107.6–337.0) versus
136.8 (83.6–212.8) ng/L, P = 0.048; women: 292.4 (174.2–
419.9) versus 160.4 (115.3–258.5) ng/L, P = 0.001, Fig. 2].
On a sex-specific multiple logistic regression model,
independent, significant impact factors for subclinical
atherosclerosis in both genders were identified: for men
these included age, BMI, smoking history, family history
of CVD, fasting glucose, fasting insulin, hypertension,
dyslipidemia and serum FGF21; for women these in-
cluded age, BMI, smoking history, family history of
CVD, menopausal status, fasting glucose, fasting insulin,
hypertension, dyslipidemia and serum FGF21 (Model 1,
Table 3). Elevated serum FGF21 was found to be an in-
dependent impact factor for subclinical atherosclerosis
in the full regression model, in which all relevant con-
founding variables were entered for both men and
women (P = 0.014 and P = 0.029, respectively). Family
history of CVD and BMI were also independently associ-
ated with subclinical atherosclerosis in men (P = 0.004
and P = 0.036, respectively), while age and family history
of CVD were independently associated with subclinical
atherosclerosis in women (P = 0.021 and P = 0.034, re-
spectively). If BMI was replaced by WC in models of
both genders (Model 2), FGF21 remained as a significant
impact factor associated with subclinical atherosclerosis
in type 2 diabetes in both men and women (P = 0.026
and P = 0.037, respectively).Fig. 2 Serum FGF21 levels in type 2 diabetic patients with subclinical
atherosclerosis or without subclinical atherosclerosis. Serum levels of
FGF21 in patients with subclinical atherosclerosis (subAS) or patients
without subclinical atherosclerosis (non-subAS) in the entire cohort,
men or women subgroup are shown as box-and-whisker plots. The
horizontal line in the middle of each box indicates the median value;
the top and bottom borders of the boxes represent the 75th and 25th
percentiles, respectively; the whiskers represent the 10th and 90th
percentiles, respectively; and the dots represent the outliersDiscussion
In the current study we report for the first time that
serum FGF21 levels are strikingly elevated in newly diag-
nosed type 2 diabetic patients with subclinical atheroscler-
osis compared to those without subclinical atherosclerosis.
This observation remained true in both men and women
when the results were analyzed independently. Moreover,
we detected a strong association of FGF21 with carotid
IMT in women as well as iliac IMT in men and women
with type 2 diabetes.
Several risk factors have been proposed as potential
markers for improved detection of subclinical athero-
sclerosis. In particular, physical measurements such as
neck circumference [21] and abdominal adiposity [22];
inflammatory biomarkers such as C-reactive protein
(CRP) [23]; lipid parameters such as oxidized LDL; ad-
hesion molecules such as E-selectin; cytokines such as
osteoprotegerin; and adipokines such as leptin [24],
have all been associated with subclinical atherosclerosis
in different ethnic groups. However, each of these fac-
tors provides only a rather limited information for car-
diovascular risk. Therefore, identification of additional
risk factors and/or biomarkers for atherosclerosis may
help a better understanding of the disease, which in turn
facilitate early diagnosis.
Recently, more studies have indicated the relevance of
FGF21 to CVD in humans. Chow et al. found that ele-
vated serum FGF21 levels were associated with carotid
IMT independent of cardiovascular risk factors [15]. In
separate group studies, Lin et al. and Shen et al. exam-
ined patients using diagnostic criteria and coronary ar-
teriography, respectively, to show that serum FGF21
levels were significantly higher in CHD patients com-
pared to healthy controls [13, 14]. An et al. showed that
type 2 diabetic subjects with carotid artery plaques
expressed higher levels of FGF21 than those without
plaque [16]. Arterial stiffness, as measured by brachial-
ankle pulse wave velocity, has also been reported to be
related to FGF21 levels in obese women [25]. Surpris-
ingly, the association between arterial stiffness and
FGF21 was diminished by a 3 month exercise program,
suggesting that hyper-FGF21-nemia is reversible. In
addition, the presence of higher serum FGF21 was asso-
ciated with a significant increase in combined cardiovas-
cular morbidity and mortality [26]. Our study, which is
focused on the early stage of atherosclerosis in newly di-
agnosed type 2 diabetes patients, suggests that FGF21 is
linked to the initiation and formation of atherosclerosis.
The role of FGF21 in atherosclerosis has been highlighted
recently. FGF21 was found to be upregulated and secreted
from hepatocytes and adipocytes into the circulation to
protect ischemic cardiomyocytes [27]. FGF21 is also
expressed in endothelial cells and can be stimulated by high
glucose, which in turn protects against cellular damage and
Table 3 Multiple logistic regression analysis showing the parameters with significant independent associations with subclinical
atherosclerosis
Men (n = 107) Women (n = 105)
Model 1 Model 2 Model 1 Model 2
Parameters OR(95 % CI) P value OR(95 % CI) P value OR(95 % CI) P value OR(95 % CI) P value
Age 1.01(0.95–1.07) 0.828 0.99(0.93–1.05) 0.718 1.17(1.02–1.33) 0.021 1.15(1.01–1.30) 0.040
Smoking 1.07(0.30–3.73) 0.921 1.25(0.38–4.15) 0.715 3.68(0.13–104.52) 0.455 4.23(0.18–97.23) 0.368
Family history of cardiovascular diseases 6.411(1.82–22.56) 0.004 4.18(1.31–13.35) 0.016 4.02(1.11–14.55) 0.034 4.16(1.16–14.98) 0.029
Menopause status - - - - 1.24(0.08–19.68) 0.877 1.39(0.08–23.30) 0.818
Body mass index 1.27(1.02–1.59) 0.036 - - 1.18(0.90–1.55) 0.235 - -
Waist circumference - - 0.98(0.90–1.05) 0.540 - - 1.02(0.95–1.09) 0.661
Hypertension 0.82(0.19–3.50) 0.790 1.11(0.28–4.43) 0.887 0.59(0.15–2.36) 0.459 0.63(0.16–2.49) 0.510
Dyslipidemia 0.35(0.10–1.22) 0.100 0.38(0.11–1.28) 0.117 3.36(0.71–15.77) 0.125 3.18(0.70–14.53) 0.135
Fasting glucose 0.91(0.72–1.15) 0.435 0.96(0.78–1.19) 0.714 1.04(0.91–1.19) 0.583 1.03(0.90–1.17) 0.677
Fasting insulina 0.46(0.15–1.43) 0.181 0.79(0.28–2.25) 0.656 0.63(0.20–1.96) 0.420 0.87(0.32–2.34) 0.781
Fibroblast growth factor 21a 2.20(1.17–4.13) 0.014 1.98(1.09–3.60) 0.026 3.08(1.12–8.42) 0.029 2.90(1.07–7.86) 0.037
aLog-transformed before analyses
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endothelial cells [28]. Therefore, it is possible that in differ-
ent tissues FGF21 expression and secretion is induced by
atherogenic factors as a defense response to counteract the
disease. FGF21 may mediate its anti-atherosclerotic effects
via induction of adiponectin in adipocytes and suppression
of cholesterol synthesis in hepatocytes [29]. However, the
protective effects of FGF21 may be inhibited due to down-
regulation of its co-receptor β-Klotho caused by TNF-α in
the chronic inflammatory state, leading to FGF21 resistance
[30]. The presence of elevated FGF21 levels in patients with
subclinical atherosclerosis may also be attributed to a com-
pensatory response, secondary to FGF21 resistance.
In this study, serum FGF21 was associated with carotid
and iliac IMT in women but only iliac IMT in men. A
previous study also showed gender-specific differences
in the association between serum FGF21 and carotid
IMT [15]. One explanation for this is the difference in
risk factors between men and women in this study. As
male participants in our study had a higher prevalence
of smoking and higher serum levels of TG, the impact of
FGF21 on carotid atherosclerosis might be outweighed
by these confounding risk factors. Another explanation
might be the contribution of sex hormones to athero-
sclerosis. One study showed a negative correlation of
serum FGF21 and estradiol which can protect premeno-
pausal women from CVD [31]. The different mecha-
nism(s) underlying the association of FGF21 and sex
hormones with respect to CVD remain to be established.
In addition, we found a positive correlation between
serum FGF21 with iliac IMT but not with femoral IMT
in both genders, which suggests that there may be some
differences in the pathogenesis of atherosclerosis in
these 2 vessels even though they are nearby. It ispossible that shear stress applied to the femoral artery
might be different from that applied to the common iliac
artery because of the vascular curvature existing at the
femoral site, which may lead to disturbed blood flow
that influences atherogenesis [32].
In line with previous findings [13, 15], we found that
serum FGF21 levels were positively correlated to TG
and fasting glucose. We failed to observe a significant
association between FGF21 and fasting insulin, which
has been proven by other authors [9, 33], suggesting that
FGF21 might play a role in glucose metabolism but not
through insulin secretion or actions. Both fasting glucose
and postprandial glucose levels contribute to HbA1c,
however there was no significant correlation between
FGF21 and 2 h-postprandial glucose (data not shown),
which is a possible reason for the lack of association be-
tween FGF21 and HbA1c.
Intriguingly, the association between serum FGF21
and WC was only present in women, which was consist-
ent with another study [15]. A reason for this may be
that in females, not only visceral adipose accumulation,
but also subcutaneous adipose accumulation contributes
to WC. FGF21 mRNA expression was shown to be 1-
fold higher in subcutaneous adipose tissue than in vis-
ceral adipose tissue in subjects with a BMI < 40 kg/m2,
whereas in subjects with a BMI > 40 kg/m2, FGF21
mRNA expression was similar in both tissues [5]. This
suggests that the production of FGF21 from subcutane-
ous adipose tissue is a more important source for ele-
vated serum FGF21, with the exception of the liver.
The median of serum FGF21 in the current study was
different from our previous work both of which re-
cruited type 2 diabetic patients but quite differed in
sample size [8]. Interindividual variation in FGF21 levels
Xiao et al. Cardiovascular Diabetology  (2015) 14:72 Page 7 of 8may partially account for this difference since it has been
reported that even healthy individuals show a wide range
in serum FGF21 (21–5300 ng/L) [34]. Another reason is
that given the non-normal distribution of serum FGF21
levels, we can only use the median which is less sensitive
and efficient than the mean to describe the data.
Limitations
Our study has several limitations. First, our present study
is limited by the lack of measurements for NAFLD. Sev-
eral studies have shown that FGF21 is increased in
NAFLD [10, 11]. It has also been reported that liver fat is
the only measure of adiposity that influences circulating
FGF21 levels [35]. In addition, another study found that
subjects with coronary artery disease had significantly
higher serum FGF21 when the presence of NAFLD was
taken into account [14]. Therefore, further studies will be
needed to elucidate the impact of NAFLD on the associ-
ation of FGF21 and subclinical atherosclerosis. Second,
the current study population included only subjects with
type 2 diabetes, therefore our findings may not be directly
applicable to the general population because of the
sampling bias.
Conclusions
In our study, we have shown that serum FGF21 is ele-
vated in newly diagnosed type 2 diabetes, and positively
correlates with carotid and iliac lesions in patients with
subclinical atherosclerosis, especially in women. Indeed,
high levels of FGF21 may be a compensatory reaction to
offset atherosclerosis, suggesting that FGF21 might be a
potential therapeutic target for this disease.
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